https://www.aigom.it/wp-content/uploads/2025/06/ART24.6.png1272888Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-06-23 08:16:072025-06-23 08:16:07ZOLBETUXIMAB PLUS mFOLFOX6 IN PATIENTS WITH CLDN18.2-positive, HER2-negative, UNTREATED, LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA (SPOTLIGHT): A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 TRIAL.
https://www.aigom.it/wp-content/uploads/2025/06/ART3.6.png1350960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-06-03 07:58:002025-06-03 07:58:00DATOPOTAMAB DERUXTECAN IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH ACTIONABLE GENOMIC ALTERATIONS: RESULTS FROM THE PHASE II TROPION-Lung05 STUDY.
